The FDA approval of Kresladi (marnetegragene autotemcel) on March 26, 2026, is indeed a watershed moment for Rocket Pharmaceuticals and the LAD-I community. However, your question regarding the cost per patient touches on the most complex challenge in modern medicine: the “one-and-done” curative price tag.

While Rocket Pharmaceuticals has not yet publicly released the official list price (WAC) for Kresladi—stating they will reveal pricing closer to the Q4 2026 commercial rollout—we can perform a “SME-level” analysis of the expected costs based on current market benchmarks and the unique economics of this therapy.

1. The Multi-Million Dollar Benchmark

In the current 2024–2026 landscape, gene therapies for ultra-rare diseases are almost exclusively priced between $2.5 million and $4.5 million per dose.

• Lenmeldy (MLD): $4.25 million (current record holder).

• Hemgenix (Hemophilia B): $3.5 million.

• Skysona (CALD): $3.0 million.

Given that LAD-I affects a “single-digit” number of patients per year in the U.S., Kresladi will likely fall into the higher end of this bracket ($3M–$4M) to recoup the heavy R&D and specialized manufacturing costs.

2. The “Hidden” Value: The Priority Review Voucher (PRV)

A critical piece of the “cost” puzzle is the Rare Pediatric Disease Priority Review Voucher Rocket received upon approval.

• These vouchers are transferable and are currently trading on the secondary market for approximately $200 million.
• For a company with ~$189M in cash, selling this voucher essentially doubles their runway. This “subsidy” from the FDA helps offset the fact that a $4M price tag on only 5–10 patients a year ($20M–$40M revenue) would otherwise struggle to sustain a biotech company.

3. Total Cost of Care vs. List Price

As a researcher, you know the list price is only part of the “HEOR” (Health Economics and Outcomes Research) story. The true cost per patient includes:

• • Conditioning Regimen: Patients must undergo myeloablative chemotherapy (busulfan) to “clear space” in the bone marrow before Kresladi infusion.

  • Inpatient Stay: Treatment requires a specialized transplant center stay, often lasting 4–6 weeks, to monitor for infections and engraftment.

  • Offset Costs: Without Kresladi, severe LAD-I has a 75% mortality rate by age two. Survivors require lifelong, expensive prophylactic antibiotics, hospitalizations for severe infections, and potentially a bone marrow transplant (BMT), which itself can cost over $1 million with a high risk of Graft-vs-Host Disease (GvHD).

4. Market Access & Sustainability

Rocket’s CEO has noted a “minimal viable launch” strategy. This means they aren’t building a massive commercial machine but rather focusing on a few “Centers of Excellence.”

• Reimbursement: Payers are increasingly moving toward value-based agreements (VBAs) or “milestone-based payments,” where the pharmaceutical company only keeps the full payment if the patient remains infection-free for several years.

Summary Table: Kresladi Economic Outlook

While the price per patient is staggering to the public, the “ground truth” in 2026 remains that these therapies are priced as a front-loaded investment to eliminate decades of catastrophic medical expenses and, more importantly, to save lives that were previously considered untreatable.